SEC Comment Letter for Summit Therapeutics Inc. (SMMT) (CIK 0001599298) (SMMT) — May 24, 2018
Summit Therapeutics Inc. (SMMT) (CIK 0001599298)
Date: May 24, 2018 · CIK: 0001599298 · Accession: 0000000000-18-016083
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-224938
Letter
May 23, 2018 Glyn Edwards Chief Executive Officer Summit Therapeutics plc 136a Eastern Avenue Milton Park, Abingdon Oxfordshire OX14 4SB United Kingdom Re:Summit Therapeutics plc Registration Statement on Form F-3 Filed May 15, 2018 File No. 333-224938 Dear Mr. Edwards: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at (202) 551-5019 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Brian A. Johnson, Esq.
Show Raw Text
May 23, 2018
Glyn Edwards
Chief Executive Officer
Summit Therapeutics plc
136a Eastern Avenue
Milton Park, Abingdon
Oxfordshire OX14 4SB
United Kingdom
Re:Summit Therapeutics plc
Registration Statement on Form F-3
Filed May 15, 2018
File No. 333-224938
Dear Mr. Edwards:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at (202) 551-5019 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Brian A. Johnson, Esq.